Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Lisa Melamed"'
Autor:
Daniel P. Cahill, Hiroaki Wakimoto, Julie J. Miller, Lisa Melamed, Seamus Rafferty, Megha Subramanian, Fumi Higuchi, Kensuke Tateishi, Christine K. Lee, Hiroaki Nagashima
NAD+ is an essential cofactor metabolite and is the currency of metabolic transactions critical for cell survival. Depending on tissue context and genotype, cancer cells have unique dependencies on NAD+ metabolic pathways. PARPs catalyze oligomerizat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4548a0ba9bccfaa3383ec4606014a7bf
https://doi.org/10.1158/2159-8290.c.6547864.v1
https://doi.org/10.1158/2159-8290.c.6547864.v1
Autor:
Daniel P. Cahill, Hiroaki Wakimoto, Julie J. Miller, Lisa Melamed, Seamus Rafferty, Megha Subramanian, Fumi Higuchi, Kensuke Tateishi, Christine K. Lee, Hiroaki Nagashima
shRNA and Control shRNA Cell Lines, Molecular Analyses, 2-HG Quantitation, Western blot analysis, Immunohistochemistry, TUNEL assay, In Vivo Studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65c8716f95ed0c3b990e58f050aa749e
https://doi.org/10.1158/2159-8290.22535455.v1
https://doi.org/10.1158/2159-8290.22535455.v1
Autor:
REUTER, ANNIE
Publikováno v:
Billboard. 6/29/2019, Vol. 131 Issue 16, p39-39. 1/2p. 1 Color Photograph.
Publikováno v:
Neuro-Oncology. 24:vii90-vii91
Isocitrate dehydrogenase (IDH) 1 or 2 mutant gliomas have unique metabolic characteristics and DNA damage response. Radiotherapy and chemotherapy has been proven to be an effective treatment for IDH mutant gliomas. A key mediator of DNA damage respon
Autor:
Daniel P. Cahill, Christine K. Lee, Alexandria Fink, Hiroaki Wakimoto, Megha Subramanian, Julie J. Miller, Lisa Melamed, Kensuke Tateishi, Hiroaki Nagashima, Shilpa S. Tummala, Jack A Banagis
Publikováno v:
Neuro Oncol
Background Isocitrate dehydrogenase (IDH)–mutant tumors exhibit an altered metabolic state and are critically dependent upon nicotinamide adenine dinucleotide (NAD+) for cellular survival. NAD+ steady-state levels can be influenced by both biosynth
Publikováno v:
Neuro Oncol
Despite initial responsiveness to standard treatments like radiation and chemotherapy, IDH mutant gliomas inevitably recur, become more clinically aggressively and lead to untimely death. Recurrent IDH mutant tumors are less responsive to conventiona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82d7928efaee91fc9e6bd19f83134cbd
https://europepmc.org/articles/PMC8598806/
https://europepmc.org/articles/PMC8598806/
Publikováno v:
Neuro-Oncology. 24:vii218-vii218
Despite initial responsiveness to standard treatments like radiation and chemotherapy, IDH mutant gliomas inevitably recur, become more clinically aggressive, and lead to untimely death. The aggressive change in clinical outcome is driven by insensit
Autor:
Daniel P. Cahill, Hiroaki Nagashima, Julie J. Miller, Christine K. Lee, Kensuke Tateishi, Lisa Melamed, Fumi Higuchi, Hiroaki Wakimoto, Seamus Rafferty, Megha Subramanian
Publikováno v:
Neuro Oncol
Mutations in IDH1 or IDH2 characterize the majority of diffuse infiltrative gliomas of younger adulthood. DNA alkylator chemotherapy has proven to be an effective treatment for IDH mutant glioma, yet recurrences remain frequent and improved treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f8ecf29b0f135038064386b25a5b1a6
https://europepmc.org/articles/PMC7650933/
https://europepmc.org/articles/PMC7650933/
Autor:
Fumi Higuchi, Daniel P. Cahill, Seamus Rafferty, Julie J. Miller, Lisa Melamed, Hiroaki Wakimoto, Christine K. Lee, Kensuke Tateishi, Megha Subramanian, Hiroaki Nagashima
Publikováno v:
Cancer Discov
NAD+ is an essential cofactor metabolite and is the currency of metabolic transactions critical for cell survival. Depending on tissue context and genotype, cancer cells have unique dependencies on NAD+ metabolic pathways. PARPs catalyze oligomerizat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::917d9b18cdc4b1bd9f2145bc979d33b1
https://europepmc.org/articles/PMC7642007/
https://europepmc.org/articles/PMC7642007/
Autor:
Hiroaki Nagashima, Daniel P. Cahill, Hiroaki Wakimoto, Julie J. Miller, Christine K. Lee, Lisa Melamed
Publikováno v:
Neuro Oncol
IDH1-mutant gliomas are characteristically sensitive to NAD+ depletion. It is known that NAD+ can move between cells through gap junctions, which provides an opportunity for treatments that prevent NAD+ sharing across tumor cells, effectively decreas